poisar

Stocks · News reference

Vivos Therapeutics shares are trading higher after the company announced the execution by management of a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

    Vivos Therapeutics reported Q3 2026 revenue of $6.4 million, up 24% quarter-over-quarter, with operating loss improving 18% year-over-year to $3.9 million. The company reduced annual operating costs by $5 million, exchanged $6.1 million of debt for equity, and regained Nasdaq compliance with stockholders' equity requirements following the October 2026 SOD Sciences acquisition. Management expects new clinical initiatives and payer contract renegotiations to contribute to revenue growth beginning Q4 2026.

  2. Zacks Investment ResearchZacks.Com

    Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates

    Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

  3. SEC EDGARSEC EDGAR

    8-K filing — Vivos Therapeutics, Inc. (VVOS)

    Filed: 2026-11-17 AccNo: 0001493152-26-052658 Size: 369 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits